Drug intelligence / Profile preview

IDV184001AN

Development stage: Unknown
Lead developer: Indivior
Modality: Small Molecules
Administration: Oral

Overview

IDV184001AN is an investigational small molecule drug developed by Indivior for the treatment of opioid abuse. It is currently being studied in Phase 1 clinical trials to characterize its absorption, metabolism, excretion, and mass balance following a single oral dose in healthy adult male participants. The study involves administration of a radiolabeled version ([14C]-IDV184001AN) to facilitate pharmacokinetic analysis. The mechanism of action has not been disclosed publicly as of this time[1][2][3][5][7].

Other names: [14C]-IDV184001AN[14C]-IDV184001

Beyond the preview

Go deeper on IDV184001AN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDV184001AN.

Explore the full profile